Purple Biotech (PPBT) - Net Assets
Based on the latest financial reports, Purple Biotech (PPBT) has net assets worth $9.66 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.57 Million) and total liabilities ($7.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PPBT total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.66 Million |
| % of Total Assets | 54.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -85.16% |
| 10-Year Change | -27.84% |
| Growth Volatility | 359.63 |
Purple Biotech - Net Assets Trend (2013–2025)
This chart illustrates how Purple Biotech's net assets have evolved over time, based on quarterly financial data. Check PPBT tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Purple Biotech (2013–2025)
The table below shows the annual net assets of Purple Biotech from 2013 to 2025. For live valuation and market cap data, see market value of Purple Biotech.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.66 Million | -70.65% |
| 2024-12-31 | $32.91 Million | -4.04% |
| 2023-12-31 | $34.30 Million | -27.18% |
| 2022-12-31 | $47.10 Million | -27.66% |
| 2021-12-31 | $65.11 Million | -18.36% |
| 2020-12-31 | $79.75 Million | +634.30% |
| 2019-12-31 | $10.86 Million | -1.30% |
| 2018-12-31 | $11.00 Million | +28.06% |
| 2017-12-31 | $8.59 Million | -35.80% |
| 2016-12-31 | $13.38 Million | +41.96% |
| 2015-12-31 | $9.43 Million | +1119.79% |
| 2014-12-31 | $773.00K | +181.71% |
| 2013-12-31 | $-946.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Purple Biotech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16647634700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $28.31 Million | 291.44% |
| Other Components | $152.48 Million | 1569.72% |
| Total Equity | $9.71 Million | 100.00% |
Purple Biotech Competitors by Market Cap
The table below lists competitors of Purple Biotech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Future Supply Chain Solutions Limited
NSE:FSC
|
$1.31 Million |
|
Margaret Lake Diamonds Inc
V:DIA
|
$1.31 Million |
|
Aclarion Inc
NASDAQ:ACON
|
$1.31 Million |
|
Mobius Investment Trust PLC
LSE:MMIT
|
$1.31 Million |
|
Gafisa S.A
SA:GFSA3
|
$1.30 Million |
|
VULTUS AB
F:V06
|
$1.30 Million |
|
A Luzon Real Estate & Finance Ltd
TA:LZNR
|
$1.30 Million |
|
Siwani Makmur Tbk
JK:SIMA
|
$1.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Purple Biotech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,860,000 to 9,713,849, a change of -23,146,151 (-70.4%).
- Net loss of 26,809,000 reduced equity.
- New share issuances of 3,153,000 increased equity.
- Other comprehensive income increased equity by 28,407,561.
- Other factors decreased equity by 27,897,712.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.81 Million | -275.99% |
| Share Issuances | $3.15 Million | +32.46% |
| Other Comprehensive Income | $28.41 Million | +292.44% |
| Other Changes | $-27.90 Million | -287.2% |
| Total Change | $- | -70.44% |
Book Value vs Market Value Analysis
This analysis compares Purple Biotech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-23073.17 | $1.40 | x |
| 2014-12-31 | $6901.79 | $1.40 | x |
| 2015-12-31 | $19602.91 | $1.40 | x |
| 2016-12-31 | $4652.42 | $1.40 | x |
| 2017-12-31 | $1546.74 | $1.40 | x |
| 2018-12-31 | $1481.70 | $1.40 | x |
| 2019-12-31 | $1076.42 | $1.40 | x |
| 2020-12-31 | $1380.68 | $1.40 | x |
| 2021-12-31 | $738.01 | $1.40 | x |
| 2022-12-31 | $518.90 | $1.40 | x |
| 2023-12-31 | $309.10 | $1.40 | x |
| 2024-12-31 | $200.39 | $1.40 | x |
| 2025-12-31 | $4047.44 | $1.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Purple Biotech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -275.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.81x
- Recent ROE (-275.99%) is below the historical average (-114.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.53 Million |
| 2014 | -679.43% | 0.00% | 0.00x | 2.28x | $-5.33 Million |
| 2015 | -44.56% | 0.00% | 0.00x | 1.15x | $-5.14 Million |
| 2016 | -90.59% | 0.00% | 0.00x | 1.11x | $-13.46 Million |
| 2017 | -166.51% | -12177.00% | 0.01x | 1.94x | $-12.91 Million |
| 2018 | -49.42% | -520.00% | 0.07x | 1.40x | $-6.25 Million |
| 2019 | -56.13% | -585.00% | 0.07x | 1.41x | $-6.89 Million |
| 2020 | -35.27% | -2799.90% | 0.01x | 1.06x | $-35.94 Million |
| 2021 | -28.36% | 0.00% | 0.00x | 1.08x | $-24.87 Million |
| 2022 | -46.19% | 0.00% | -0.02x | 1.16x | $-26.36 Million |
| 2023 | -0.06% | -10.15% | 0.00x | 1.30x | $-3.44 Million |
| 2024 | -22.03% | 0.00% | 0.00x | 1.13x | $-10.53 Million |
| 2025 | -275.99% | 0.00% | 0.00x | 1.81x | $-27.78 Million |
Industry Comparison
This section compares Purple Biotech's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,074,129
- Average return on equity (ROE) among peers: -103.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Purple Biotech (PPBT) | $9.66 Million | 0.00% | 0.82x | $1.30 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $5.82 Million | -168.16% | 1.54x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.66 Billion |
About Purple Biotech
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more